Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
ASRT.US
id: 965

Assertio Holdings mis-representation and mis-management of Spectrum Acquistion causing subsequent Aug 2023 46% decline and Nov 2023 39% declienes

Have been a shareholder in Spectrum Pharma $SPPI and its acquirer Assertio Holdings $ASRT for nearly 4 years and have suffered continued losses due to the companies mis-management of their FDA approval process for drug Rolvedon which caused a 9 month delay and share declines. Also the terms of the acquistion by $ASRT were very suspect and not transprent and caused the share price within 6 months of the merger to declie 90% due to the leadership giving mis-leading and false guidance about the combined companies revenue forecast and gross underperformance which caused massive share drops of 46% in Aug 2023 earnings call and again 39% in Dec 4 earnings report.
Case Status
Inactive Investigation
Alleged Offence
Mismanagement
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Negligence
Omissions
Suspected Party
Directors
Management
Shareholder
Security Type
Stocks
Trade Direction
Long
Shock Event Date
08/04/2023
Collecting participants…

Assertio Therapeutics Inc

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository soluti...

    Ticker
    ASRT.US
    ISIN
    US04546C2052
    CIK
    0001005201
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Country
    USA
    Address
    100 South Saunders Road, Lake Forest, IL, United States, 60045